TICKERNERD
Menu
CLPTCLPTHealthcare · Medical Devices

CLPT Stock Forecast: ClearPoint Neuro, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$11
−0.19% on the day

The 2 Wall Street analysts covering ClearPoint Neuro, Inc. hold a median 12-month price target of $24 — +120.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$342.0M
Ticker Nerd rank
28/ 100
Median analyst target
$24
Analysts covering
2
Revenue$10.9M+18.1% y/y
Operating income−$10.2M
Net income−$11.3M
Free cash flow−$7.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+16.7%
1M
−12.6%
YTD
−22.0%
1Y
−54.9%
From 52W high
−54.9%
From 52W low
+23.2%
$9
$24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLPT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ClearPoint Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
28/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
72
Size
58
Quality
50
Growth
50
Value
39
Momentum
35
Accruals
23
Volatility
15
Issuance
10

Revisions (72): Analysts have, on balance, been raising their forecasts.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CLPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Jan 26Apr 26Jul 26Oct 26CLPTHigh $25Median $24Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $22Median $24High $25

The green dot is the last close — the median target sits +120.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Oct 2026StifelMaintainsBuy$22 → $18
18 June 2026B. Riley SecuritiesMaintainsBuy—
18 June 2026B. Riley SecuritiesMaintainsBuy$20 → $30
18 Mar 2026B. Riley SecuritiesMaintainsBuy—
5 Mar 2026B. Riley SecuritiesMaintainsBuy—
1 Aug 2025StifelMaintainsBuy—
25 Apr 2025B. Riley SecuritiesMaintainsBuy—
1 Apr 2025StifelMaintainsBuy—
28 Jan 2025B. Riley SecuritiesMaintainsBuy—
21 Jan 2025Lake StreetMaintainsBuy—
27 Aug 2024Lake StreetMaintainsBuy—
13 Mar 2024StifelReiteratesBuy—
24 Oct 2023StifelInitiatesBuy—
9 Aug 2023Lake StreetMaintainsBuy—
16 Feb 2023B. Riley SecuritiesReinstatesBuy$14
5 Apr 2022B. Riley SecuritiesReinstatesBuy$15
18 Mar 2021Lake StreetInitiatesBuy—
17 July 2020B. Riley SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CLPT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CLPT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, ClearPoint Neuro, Inc. returned −54.9% against +12.4% for the S&P 500, dividends included.

CLPT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26CLPTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CLPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

ClearPoint Neuro, Inc. (CLPT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.9×

Cheaper than 94% of US stocks

Price / sales
7.5×

Cheaper than 17% of US stocks

Price / book
12.5×

Cheaper than 7% of US stocks

EV / EBITDA
−12.7×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
36.3%

Higher than 81% of US stocks

Earnings growth (YoY)
18.1%

Higher than 57% of US stocks

Gross margin
61.7%

Higher than 75% of US stocks

Operating margin
−52.4%

Higher than 17% of US stocks

Net margin
−79.4%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−167.5%

Higher than 9% of US stocks

Return on assets
−21.9%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ClearPoint Neuro, Inc. (CLPT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ClearPoint Neuro, Inc. has a market value of $342.0M and an enterprise value of $369.5M.

  • Revenue in the twelve months to 30 June 2026: $42.3M. The latest quarter grew 36.3% year on year.

  • Net income over the same four quarters: −$34.6M, a −81.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$31.3M.

  • Shares outstanding: 30.5M.

  • Trailing P/E: −11.9×; forward P/E: −9.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ClearPoint Neuro, Inc. employs 172 people — $246K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

CLPT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CLPTClearPoint Neuro, Inc.$342.0M28
MOBIMobia Medical, Inc.$350.0M3
OFIXOrthofix Medical, Inc.$359.2M68
CVCapsoVision, Inc.$363.4M21
VMDViemed Healthcare, Inc.$367.6M96
QSIQuantum-Si, Inc.$314.6M43
SIShoulder Innovations, Inc.$398.3M35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ClearPoint Neuro, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLPT news & analysis

What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call

MarketBeat · 29 Oct 2026positive

ClearPoint Neuro reported third-quarter 2026 revenue growth of 36%, with sales increasing across its biologics and drug-delivery, neurosurgery navigation and therapy, and capital equipment and software businesses. Management said it is investing in clinical support, laboratory capabilities and product development ahead of anticipated cell and gene therapy trial activity and potential commercial launches.

Why it matters — The update gives CLPT watchers information on revenue growth across business lines and investments tied to potential future trial activity and launches.

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates

Zacks Investment Research · 29 Oct 2026neutral

ClearPoint Neuro reported a third-quarter loss of $0.24 per share, compared with the Zacks consensus estimate of a $0.32 loss. The loss was $0.21 per share in the year-ago quarter.

Why it matters — CLPT watchers may note the smaller loss than estimated alongside a wider loss per share than a year earlier.

ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript

Seeking Alpha · 29 Oct 2026neutral

Seeking Alpha published a transcript of ClearPoint Neuro, Inc.’s Q3 2026 earnings call. The excerpt provides no details from the call.

Why it matters — CLPT watchers can note the availability of the quarterly earnings-call transcript, though the excerpt does not provide business or financial updates.

ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026

Accesswire · 14 Oct 2026neutral

ClearPoint Neuro announced it will release its third-quarter 2026 financial results after market close on October 28, 2026. The company also invited investors and analysts to listen to a live review broadcast at 4:30 p.m. that day.

Why it matters — CLPT watchers can note the scheduled date and time for the company's quarterly results and review.

FAQ

Frequently asked questions about CLPT stock

What is the CLPT stock price forecast for 2026-2027?

The 2 Wall Street analysts covering ClearPoint Neuro, Inc. have a median 12-month price target of $24, with estimates ranging from $22 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLPT stock a buy right now?

Of the 2 analysts covering ClearPoint Neuro, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ClearPoint Neuro, Inc. 28 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLPT?

As at 31 Oct 2026, ClearPoint Neuro, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).

Will CLPT stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +120.2% from the last close, and Ticker Nerd's factor model ranks ClearPoint Neuro, Inc. 28 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLPT stock forecast for 2030?

No analyst covering ClearPoint Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $25 over the next 12 months.

How has CLPT stock performed over the past year?

ClearPoint Neuro, Inc. returned -54.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ClearPoint Neuro, Inc. do?

ClearPoint Neuro Inc. is a medical technology company focused on precision navigation and delivery solutions for complex neurological procedures.

What is the latest news on CLPT?

The most recent item we track (MarketBeat, 29 Oct 2026): "What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call". ClearPoint Neuro reported third-quarter 2026 revenue growth of 36%, with sales increasing across its biologics and drug-delivery, neurosurgery navigation and therapy, and capital equipment and software businesses. Management said it is investing in clinical support, laboratory capabilities and product development ahead of anticipated cell and gene therapy trial activity and potential commercial launches.

Company

About ClearPoint Neuro, Inc.

ClearPoint Neuro Inc. is a medical technology company focused on precision navigation and delivery solutions for complex neurological procedures. The company develops and commercializes platforms used in minimally invasive brain and spine interventions, combining hardware, disposable instruments, and software that support surgical planning, targeting, and procedure monitoring. Its product portfolio includes MRI-guided navigation systems, laser therapy tools, and therapy-delivery components designed to help clinicians access hard-to-reach areas of the central nervous system with greater control. ClearPoint Neuro also provides enabling services for cell, gene, and drug delivery programs, supporting medical and research partners with preclinical and clinical development workflows. The company serves healthcare and research centers across multiple global regions, making it an important specialist in image-guided neurosurgical technology and therapeutic delivery.

CEO Mr. Joseph Michael Burnett · 172 employees · United States · https://www.clearpointneuro.com